30 Day Trial

ORTHOKNOW content is posted to these pages in real time.

Monthly compilations are available in PDF form.

Quarterly Review

2Q13 Revenue: Globus Medical

$107MM, +12% (U.S. $98.1MM, +11%; ex-U.S. $8.9MM, +20%)

  • Disruptive Technology $44MM, +27%
  • Innovative Fusion $63MM, +3%


  • Payer pushback appears to have stabilized
  • Pricing pressure remains in low- to mid-single-digits
  • Sales growth attributed to expansion of territories globally, greater penetration in existing territories
  • Launched 8 new products in 1H, 6 in 2Q, including LATIS laterally-expanding lumbar interbody fusion spacer: combined with REVOLVE MIS screw system, procedure is designed to maximize preservation of stabilizing muscles
  • Notes active involvement in multiple biologics projects
  • Net U.S. additions to salesforce in 1H13 surpassed full-year net additions in U.S. for every year since 2007